US20100086965A1 - Metabolic engineering of arabinose-fermenting yeast cells - Google Patents

Metabolic engineering of arabinose-fermenting yeast cells Download PDF

Info

Publication number
US20100086965A1
US20100086965A1 US12/442,013 US44201307A US2010086965A1 US 20100086965 A1 US20100086965 A1 US 20100086965A1 US 44201307 A US44201307 A US 44201307A US 2010086965 A1 US2010086965 A1 US 2010086965A1
Authority
US
United States
Prior art keywords
cell
arabinose
sequence
xylose
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/442,013
Other languages
English (en)
Inventor
Antonius Jeroen Adriaan van Maris
Jacobus Thomas Pronk
Hendrik Wouter Wisselink
Johannes Pieter Van Dijken
Aaron Adriaan Winkler
Johannes Hendrik De Winde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
DSM IP Assets BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DSM IP Assets BV filed Critical DSM IP Assets BV
Priority to US12/442,013 priority Critical patent/US20100086965A1/en
Assigned to DSM IP ASSETS B.V. reassignment DSM IP ASSETS B.V. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: VAN DIJKEN, JOHANNES P., WINKLER, AARON A., DE WINDE, JOHANNES H., PRONK, JACOBUS THOMAS, VAN MARIS, ANTONIUS J.A., WISSELINK, HENDRIK W.
Publication of US20100086965A1 publication Critical patent/US20100086965A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
    • C12P7/04—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
    • C12P7/06—Ethanol, i.e. non-beverage
    • C12P7/08—Ethanol, i.e. non-beverage produced as by-product or from waste or cellulosic material substrate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/10—Biofuels, e.g. bio-diesel
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/30—Fuel from waste, e.g. synthetic alcohol or diesel

Definitions

  • the invention relates to an eukaryotic cell having the ability to use L-arabinose and/or to convert L-arabinose into L-ribulose, and/or xylulose 5-phosphate and/or into a desired fermentation product and to a process for producing a fermentation product wherein this cell is used.
  • Fuel ethanol is acknowledged as a valuable alternative to fossil fuels. Economically viable ethanol production from the hemicellulose fraction of plant biomass requires the simultaneous fermentative conversion of both pentoses and hexoses at comparable rates and with high yields. Yeasts, in particular Saccharomyces spp., are the most appropriate candidates for this process since they can grow and ferment fast on hexoses, both aerobically and anaerobically. Furthermore they are much more resistant to the toxic environment of lignocellulose hydrolysates than (genetically modified) bacteria.
  • EP 1 499 708 describes a process for making S. cerevisiae strains able to produce ethanol from L-arabinose. These strains were modified by introducing the araA (L-arabinose isomerase) gene from Bacillus subtilis , the araB (L-ribulokinase) and araD (L-ribulose-5-P4-epimerase) genes from Escherichia coli . Furthermore, these strains were either carrying additional mutations in their genome or overexpressing a TAL1 (transaldolase) gene. However, these strains have several drawbacks. They ferment arabinose in oxygen limited conditions.
  • araA L-arabinose isomerase
  • araB L-ribulokinase
  • araD L-ribulose-5-P4-epimerase
  • WO 03/062430 and WO 06/009434 disclose yeast strains able to convert xylose into ethanol. These yeast strains are able to directly isomerise xylose into xylulose.
  • FIG. 1 Plasmid maps of pRW231 and pRW243.
  • FIG. 2 Growth pattern of shake flask cultivations of strain RWB219 ( ⁇ ) and IMS0001 ( ⁇ ) in synthetic medium containing 0.5% galactose (A) and 0.1% galactose +2% L-arabinose (B). Cultures were grown for 72 hours in synthetic medium with galactose (A) and then transferred to synthetic medium with galactose and arabinose (B). Growth was determined by measuring the OD 660 .
  • FIG. 3 Growth rate during serial transfers of S. cerevisiae IMS0001 in shake flask cultures containing synthetic medium with 2% (w/v) L-arabinose. Each datapoint represents the growth rate estimated from the OD 660 measured during (exponential) growth. The closed and open circles represent duplicate serial transfer experiments.
  • FIG. 4 Growth rate during an anaerobic SBR fermentation of S. cerevisiae IMS0001 in synthetic medium with 2% (w/v) L-arabinose. Each datapoint represents the growth rate estimated from the CO 2 profile (solid line) during exponential growth.
  • FIG. 5 Sugar consumption and product formation during anaerobic batch fermentations of strain IMS0002.
  • the fermentations were performed in 1 synthetic medium supplemented with: 20 g l ⁇ 1 arabinose (A); 20 g l ⁇ 1 glucose and 20 g l ⁇ 1 arabinose (B); 30 g l ⁇ 1 glucose, 15 g l ⁇ 1 xylose, and 15 g l ⁇ 1 arabinose (C); Sugar consumption and product formation during anaerobic batch fermentations with a mixture of strains IMS0002 and RWB218.
  • the fermentations were performed in 1 liter of synthetic medium supplemented with 30 g l ⁇ 1 glucose, 15 g l ⁇ 1 xylose, and 15 g l ⁇ 1 arabinose (D). Symbols: glucose ( ⁇ ); xylose ( ⁇ ); arabinose ( ⁇ ); ethanol calculated from cumulative CO 2 production ( ⁇ ); ethanol measured by HPLC ( ⁇ ); cumulative CO 2 production ( ⁇ ); xylitol ( ⁇ )
  • FIG. 6 Sugar consumption and product formation during an anaerobic batch fermentation of strain IMS0002 cells selected for anaerobic growth on xylose.
  • the fermentation was performed in 1 liter of synthetic medium supplemented with 20 g l ⁇ 1 xylose and 20 g l ⁇ 1 arabinose. Symbols: xylose ( ⁇ ); arabinose ( ⁇ ); ethanol measured by HPLC ( ⁇ ); cumulative CO 2 production ( ⁇ ); xylitol ( ⁇ ).
  • FIG. 7 Sugar consumption and product formation during an anaerobic batch fermentation of strain IMS0003.
  • the fermentation was performed in 1 liter of synthetic medium supplemented with: 30 g l ⁇ 1 glucose, 15 g l ⁇ 1 xylose, and 15 g l ⁇ 1 arabinose.
  • the invention relates to a eukaryotic cell capable of expressing the following nucleotide sequences, whereby the expression of these nucleotide sequences confers on the cell the ability to use L-arabinose and/or to convert L-arabinose into L-ribulose, and/or xylulose 5-phosphate and/or into a desired fermentation product such as ethanol:
  • a preferred embodiment relates to an eukaryotic cell capable of expressing the following nucleotide sequences, whereby the expression of these nucleotide sequences confers on the cell the ability to use L-arabinose and/or to convert L-arabinose into L-ribulose, and/or xylulose 5-phosphate and/or into a desired fermentation product such as ethanol:
  • Sequence identity is herein defined as a relationship between two or more amino acid (polypeptide or protein) sequences or two or more nucleic acid (polynucleotide) sequences, as determined by comparing the sequences. Usually, sequence identities or similarities are compared over the whole length of the sequences compared. In the art, “identity” also means the degree of sequence relatedness between amino acid or nucleic acid sequences, as the case may be, as determined by the match between strings of such sequences. “Similarity” between two amino acid sequences is determined by comparing the amino acid sequence and its conserved amino acid substitutes of one polypeptide to the sequence of a second polypeptide. “Identity” and “similarity” can be readily calculated by various methods, known to those skilled in the art.
  • Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include e.g. the BestFit, BLASTP, BLASTN, and FASTA (Altschul, S. F. et al., J. Mol. Biol. 215:403-410 (1990), publicly available from NCBI and other sources (BLAST Manual, Altschul, S., et al., NCBI NLM NIH Bethesda, Md. 20894). A most preferred algorithm used is EMBOSS (http://www.ebi.ac.uk/emboss/align).
  • Preferred parameters for amino acid sequences comparison using EMBOSS are gap open 10.0, gap extend 0.5, Blosum 62 matrix.
  • Preferred parameters for nucleic acid sequences comparison using EMBOSS are gap open 10.0, gap extend 0.5, DNA full matrix (DNA identity matrix).
  • amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulphur-containing side chains is cysteine and methionine.
  • Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine.
  • Substitutional variants of the amino acid sequence disclosed herein are those in which at least one residue in the disclosed sequences has been removed and a different residue inserted in its place.
  • the amino acid change is conservative.
  • Preferred conservative substitutions for each of the naturally occurring amino acids are as follows: Ala to ser; Arg to lys; Asn to gln or his; Asp to glu; Cys to ser or ala; Gln to asn; Glu to asp; Gly to pro; His to asn or gln; Ile to leu or val; Leu to ile or val; Lys to arg; gin or glu; Met to leu or ile; Phe to met, leu or tyr; Ser to thr; Thr to ser; Trp to tyr; Tyr to trp or phe; and, Val to ile or leu.
  • Nucleotide sequences encoding the enzymes expressed in the cell of the invention may also be defined by their capability to hybridise with the nucleotide sequences of SEQ ID NO.'s 2, 4, 6, 8, 16, 18, 20, 22, 24, 26, 28, 30 respectively, under moderate, or preferably under stringent hybridisation conditions.
  • Stringent hybridisation conditions are herein defined as conditions that allow a nucleic acid sequence of at least about 25, preferably about 50 nucleotides, 75 or 100 and most preferably of about 200 or more nucleotides, to hybridise at a temperature of about 65° C. in a solution comprising about 1 M salt, preferably 6 ⁇ SSC or any other solution having a comparable ionic strength, and washing at 65° C.
  • the hybridisation is performed overnight, i.e. at least for 10 hours and preferably washing is performed for at least one hour with at least two changes of the washing solution.
  • these conditions will usually allow the specific hybridisation of sequences having about 90% or more sequence identity.
  • Moderate conditions are herein defined as conditions that allow a nucleic acid sequences of at least 50 nucleotides, preferably of about 200 or more nucleotides, to hybridise at a temperature of about 45° C. in a solution comprising about 1 M salt, preferably 6 ⁇ SSC or any other solution having a comparable ionic strength, and washing at room temperature in a solution comprising about 1 M salt, preferably 6 ⁇ SSC or any other solution having a comparable ionic strength.
  • the hybridisation is performed overnight, i.e. at least for 10 hours, and preferably washing is performed for at least one hour with at least two changes of the washing solution.
  • These conditions will usually allow the specific hybridisation of sequences having up to 50% sequence identity. The person skilled in the art will be able to modify these hybridisation conditions in order to specifically identify sequences varying in identity between 50% and 90%.
  • a preferred nucleotide sequence encoding a arabinose isomerase (araA) expressed in the cell of the invention is selected from the group consisting of:
  • a preferred nucleotide sequence encoding a L-ribulokinase (AraB) expressed in the cell of the invention is selected from the group consisting of:
  • a preferred nucleotide sequence encoding a L-ribulose-5-P-4-epimerase (araD) expressed in the cell of the invention is selected from the group consisting of:
  • the codon bias index indicated that expression of the Lactobacillus plantarum araA, araB and araD genes were more favorable for expression in yeast than the prokaryolic araA, araB and araD genes described in EP 1 499 708.
  • L. plantarum is a Generally Regarded As Safe (GRAS) organism, which is recognized as safe by food registration authorities. Therefore, a preferred nucleotide sequence encodes an araA, araB or araD respectively having an amino acid sequence that is related to the sequences SEQ ID NO: 1, 3, or 5 respectively as defined above.
  • a preferred nucleotide sequence encodes a fungal araA, araB or araD respectively (e.g. from a Basidiomycete), more preferably an araA, araB or araD respectively from an anaerobic fungus, e.g.
  • a preferred nucleotide sequence encodes a bacterial araA, araB or araD respectively, preferably from a Gram-positive bacterium, more preferably from the genus Lactobacillus , most preferably from Lactobacillus plantarum species.
  • a preferred nucleotide sequence encodes a bacterial araA, araB or araD respectively, preferably from a Gram-positive bacterium, more preferably from the genus Lactobacillus , most preferably from Lactobacillus plantarum species.
  • one, two or three or the araA, araB and araD nucleotide sequences originate from a Lactobacillus genus, more preferably a Lactobacillus plantarum species.
  • the bacterial araA expressed in the cell of the invention is not the Bacillus subtilis araA disclosed in EP 1 499 708 and given as SEQ ID NO:9.
  • SEQ ID NO:10 represents the nucleotide acid sequence coding for SEQ ID NO:9.
  • the bacterial araB and araD expressed in the cell of the invention are not the ones of Escherichia coli ( E. coli ) as disclosed in EP 1 499 708 and given as SEQ ID NO: 11 and SEQ ID NO:13.
  • SEQ ID NO: 12 represents the nucleotide acid sequence coding for SEQ ID NO:11.
  • SEQ ID NO:14 represents the nucleotide acid sequence coding for SEQ ID NO:13.
  • the corresponding encoding nucleotide sequence may be adapted to optimise its codon usage to that of the chosen eukaryotic host cell.
  • the adaptiveness of a nucleotide sequence encoding the araA, araB, and araD enzymes (or other enzymes of the invention, see below) to the codon usage of the chosen host cell may be expressed as codon adaptation index (CAI).
  • CAI codon adaptation index
  • the codon adaptation index is herein defined as a measurement of the relative adaptiveness of the codon usage of a gene towards the codon usage of highly expressed genes.
  • the relative adaptiveness (w) of each codon is the ratio of the usage of each codon, to that of the most abundant codon for the same amino acid.
  • the CAI index is defined as the geometric mean of these relative adaptiveness values. Non-synonymous codons and termination codons (dependent on genetic code) are excluded. CAI values range from 0 to 1, with higher values indicating a higher proportion of the most abundant codons (see Sharp and Li, 1987, Nucleic Acids Research 15: 1281-1295; also see: Jansen et al., 2003, Nucleic Acids Res. 31(8):2242-51).
  • An adapted nucleotide sequence preferably has a CAI of at least 0.2, 0.3, 0.4, 0.5, 0.6 or 0.7.
  • expression of the nucleotide sequences encoding an ara A, an ara B and an ara D as defined earlier herein confers to the cell the ability to use L-arabinose and/or to convert it into L-ribulose, and/or xylulose 5-phosphate.
  • L-arabinose is expected to be first converted into L-ribulose, which is subsequently converted into xylulose 5-phosphate which is the main molecule entering the pentose phosphate pathway.
  • “using L-arabinose” preferably means that the optical density measured at 660 nm (OD 660 ) of transformed cells cultured under aerobic or anaerobic conditions in the presence of at least 0.5% L-arabinose during at least 20 days is increased from approximately 0.5 till 1.0 or more. More preferably, the OD 660 is increased from 0.5 till 1.5 or more. More preferably, the cells are cultured in the presence of at least 1%, at least 1.5%, at least 2% L-arabinose. Most preferably, the cells are cultured in the presence of approximately 2% L-arabinose.
  • a cell is able “to convert L-arabinose into L-ribulose” when detectable amounts of L-ribulose are detected in cells cultured under aerobic or anaerobic conditions in the presence of L-arabinose (same preferred concentrations as in previous paragraph) during at least 20 days using a suitable assay.
  • the assay is HPLC for L-ribulose.
  • a cell is able “to convert L-arabinose into xylulose 5-phosphate” when an increase of at least 2% of xylulose 5-phosphate is detected in cells cultured under aerobic or anaerobic conditions in the presence of L-arabinose (same preferred concentrations as in previous paragraph) during at least 20 days using a suitable assay.
  • a suitable assay Preferably, an HPCL-based assay for xylulose 5-phosphate has been described in Zaldivar J., et al ((2002), Appl. Microbiol. Biotechnol., 59:436-442). This assay is briefly described in the experimental part. More preferably, the increase is of at least 5%, 10%, 15%, 20%, 25% or more.
  • expression of the nucleotide sequences encoding an ara A, ara B and ara D as defined earlier herein confers to the cell the ability to convert L-arabinose into a desired fermentation product when cultured under aerobic or anaerobic conditions in the presence of L-arabinose (same preferred concentrations as in previous paragraph) during at least one month till one year.
  • a cell is able to convert L-arabinose into a desired fermentation product when detectable amounts of a desired fermentation product are detected using a suitable assay and when the cells are cultured under the conditions given in previous sentence.
  • the assay is HPLC.
  • the fermentation product is ethanol.
  • a cell for transformation with the nucleotide sequences encoding the araA, araB, and araD enzymes respectively as described above preferably is a host cell capable of active or passive xylose transport into and xylose isomerisation within the cell.
  • the cell preferably is capable of active glycolysis.
  • the cell may further contain an endogenous pentose phosphate pathway and may contain endogenous xylulose kinase activity so that xylulose isomerised from xylose may be metabolised to pyruvate.
  • the cell further preferably contains enzymes for conversion of pyruvate to a desired fermentation product such as ethanol, lactic acid, 3-hydroxy-propionic acid, acrylic acid, acetic acid, succinic acid, citric acid, malic acid, fumaric acid, an amino acid, 1,3-propane-diol, ethylene, glycerol, butanol, a ⁇ -lactam antibiotic or a cephalosporin.
  • the cell may be made capable of producing butanol by introduction of one or more genes of the butanol pathway as disclosed in WO2007/041269.
  • a preferred cell is naturally capable of alcoholic fermentation, preferably, anaerobic alcoholic fermentation.
  • the host cell further preferably has a high tolerance to ethanol, a high tolerance to low pH (i.e. capable of growth at a pH lower than 5, 4, 3, or 2.5) and towards organic acids like lactic acid, acetic acid or formic acid and sugar degradation products such as furfural and hydroxy-methylfurfural, and a high tolerance to elevated temperatures. Any of these characteristics or activities of the host cell may be naturally present in the host cell or may be introduced or modified through genetic selection or by genetic modification.
  • a suitable host cell is a eukaryotic microorganism like e.g. a fungus, however, most suitable as host cell are yeasts or filamentous fungi.
  • Yeasts are herein defined as eukaryotic microorganisms and include all species of the subdivision Eumycotina (Alexopoulos, C. J., 1962, In: Introductory Mycology, John Wiley & Sons, Inc., New York) that predominantly grow in unicellular form. Yeasts may either grow by budding of a unicellular thallus or may grow by fission of the organism.
  • Preferred yeasts as host cells belong to one of the genera Saccharomyces, Kluyveromyces, Candida, Pichia, Schizosaccharomyces, Hansenula, Kloeckera, Schwanniomyces , or Yarrowia .
  • the yeast is capable of anaerobic fermentation, more preferably anaerobic alcoholic fermentation.
  • Filamentous fungi are herein defined as eukaryotic microorganisms that include all filamentous forms of the subdivision Eumycotina. These fungi are characterized by a vegetative mycelium composed of chitin, cellulose, and other complex polysaccharides.
  • the filamentous fungi of the present invention are morphologically, physiologically, and genetically distinct from yeasts. Vegetative growth by filamentous fungi is by hyphal elongation and carbon catabolism of most filamentous fungi is obligately aerobic.
  • Preferred filamentous fungi as host cells belong to one of the genera Aspergillus, Trichoderma, Humicola, Acremonium, Fusarium , or Penicillium.
  • yeasts of the genus Saccharomyces as ethanol producer. This is due to the many attractive features of Saccharomyces species for industrial processes, i.e., a high acid-, ethanol- and osmo-tolerance, capability of anaerobic growth, and of course its high alcoholic fermentative capacity.
  • Preferred yeast species as host cells include S. cerevisiae, S. bulderi, S. barnetti, S. exiguus, S. uvarum, S. diastaticus, K. lactis, K. marxianus, K. fragilis.
  • the host cell of the invention is a host cell that has been transformed with a nucleic acid construct comprising the nucleotide sequence encoding the araA, araB, and araD enzymes as defined above.
  • the host cell is co-transformed with three nucleic acid constructs, each nucleic acid construct comprising the nucleotide sequence encoding araA, araB or araD.
  • the nucleic acid construct comprising the araA, araB, and/or araD coding sequence is capable of expression of the araA, araB, and/or araD enzymes in the host cell.
  • the nucleic acid construct may be constructed as described in e.g.
  • the host cell may comprise a single but preferably comprises multiple copies of each nucleic acid construct.
  • the nucleic acid construct may be maintained episomally and thus comprise a sequence for autonomous replication, such as an ARS sequence.
  • Suitable episomal nucleic acid constructs may e.g. be based on the yeast 2 ⁇ or pKD1 (Fleer et al., 1991, Biotechnology 9:968-975) plasmids.
  • each nucleic acid construct is integrated in one or more copies into the genome of the host cell.
  • the cell of the invention comprises a nucleic acid construct comprising the araA, araB, and/or araD coding sequence and is capable of expression of the araA, araB, and/or araD enzymes.
  • the araA, araB, and/or araD coding sequences are each operably linked to a promoter that causes sufficient expression of the corresponding nucleotide sequences in a cell to confer to the cell the ability to use L-arabinose, and/or to convert L-arabinose into L-ribulose, and/or xylulose 5-phosphate.
  • the cell is a yeast cell.
  • the invention also encompasses a nucleic acid construct as earlier outlined herein.
  • a nucleic acid construct comprises a nucleic acid sequence encoding an araA, araB and/or araD.
  • Nucleic acid sequences encoding an araA, araB, or araD have been all earlier defined herein. Even more preferably, the expression of the corresponding nucleotide sequences in a cell confer to the cell the ability to convert L-arabinose into a desired fermentation product as defined later herein. In an even more preferred embodiment, the fermentation product is ethanol. Even more preferably, the cell is a yeast cell.
  • operably linked refers to a linkage of polynucleotide elements (or coding sequences or nucleic acid sequence) in a functional relationship.
  • a nucleic acid sequence is “operably linked” when it is placed into a functional relationship with another nucleic acid sequence.
  • a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the coding sequence.
  • Operably linked means that the nucleic acid sequences being linked are typically contiguous and, where necessary to join two protein coding regions, contiguous and in reading frame.
  • promoter refers to a nucleic acid fragment that functions to control the transcription of one or more genes, located upstream with respect to the direction of transcription of the transcription initiation site of the gene, and is structurally identified by the presence of a binding site for DNA-dependent RNA polymerase, transcription initiation sites and any other DNA sequences, including, but not limited to transcription factor binding sites, repressor and activator protein binding sites, and any other sequences of nucleotides known to one of skill in the art to act directly or indirectly to regulate the amount of transcription from the promoter.
  • a “constitutive” promoter is a promoter that is active under most environmental and developmental conditions.
  • An “inducible” promoter is a promoter that is active under environmental or developmental regulation.
  • the promoter that could be used to achieve the expression of the nucleotide sequences coding for araA, araB and/or araD may be not native to the nucleotide sequence coding for the enzyme to be expressed, i.e. a promoter that is heterologous to the nucleotide sequence (coding sequence) to which it is operably linked.
  • a promoter that is heterologous to the nucleotide sequence (coding sequence) to which it is operably linked.
  • the promoter preferably is heterologous to the coding sequence to which it is operably linked, it is also preferred that the promoter is homologous, i.e. endogenous to the host cell.
  • the heterologous promoter (to the nucleotide sequence) is capable of producing a higher steady state level of the transcript comprising the coding sequence (or is capable of producing more transcript molecules, i.e. mRNA molecules, per unit of time) than is the promoter that is native to the coding sequence, preferably under conditions where arabinose, or arabinose and glucose, or xylose and arabinose or xylose and arabinose and glucose are available as carbon sources, more preferably as major carbon sources (i.e. more than 50% of the available carbon source consists of arabinose, or arabinose and glucose, or xylose and arabinose or xylose and arabinose and glucose), most preferably as sole carbon sources.
  • Suitable promoters in this context include both constitutive and inducible natural promoters as well as engineered promoters.
  • a preferred promoter for use in the present invention will in addition be insensitive to catabolite (glucose) repression and/or will preferably not require arabinose and/or xylose for induction.
  • Promotors having these characteristics are widely available and known to the skilled person. Suitable examples of such promoters include e.g. promoters from glycolytic genes, such as the phosphofructokinase (PPK), triose phosphate isomerase (TPI), glyceraldehyde-3-phosphate dehydrogenase (GPD, TDH3 or GAPDH), pyruvate kinase (PYK), phosphoglycerate kinase (PGK) promoters from yeasts or filamentous fungi; more details about such promoters from yeast may be found in (WO 93/03159).
  • PPK phosphofructokinase
  • TPI triose phosphate isomerase
  • GPD glyceraldehyde-3-phosphate dehydrogenase
  • PYK pyruvate kinase
  • PGK phosphoglycerate kinase
  • ribosomal protein encoding gene promoters are ribosomal protein encoding gene promoters, the lactase gene promoter (LAC4), alcohol dehydrogenase promoters (ADH1, ADH4, and the like), the enolase promoter (ENO), the glucose-6-phosphate isomerase promoter (PGI1, Hauf et al, 2000) or the hexose(glucose) transporter promoter (HXT7) or the glyceraldehyde-3-phosphate dehydrogenase (TDH3).
  • the sequence of the PGI1 promoter is given in SEQ ID NO:51.
  • the sequence of the HXT7 promoter is given in SEQ ID NO:52.
  • a preferred cell of the invention is a eukaryotic cell transformed with the araA, araB and araD genes of L. plantarum . More preferably, the eukaryotic cell is a yeast cell, even more preferably a S. cerevisiae strain transformed with the araA, araB and araD genes of L. plantarum . Most preferably, the cell is either CBS120327 or CBS120328 both deposited at the CBS Institute (The Netherlands) on Sep. 27, 2006.
  • nucleic acid or polypeptide molecule when used to indicate the relation between a given (recombinant) nucleic acid or polypeptide molecule and a given host organism or host cell, is understood to mean that in nature the nucleic acid or polypeptide molecule is produced by a host cell or organisms of the same species, preferably of the same variety or strain. If homologous to a host cell, a nucleic acid sequence encoding a polypeptide will typically be operably linked to another promoter sequence or, if applicable, another secretory signal sequence and/or terminator sequence than in its natural environment.
  • the term “homologous” means that one single-stranded nucleic acid sequence may hybridize to a complementary single-stranded nucleic acid sequence.
  • the degree of hybridization may depend on a number of factors including the amount of identity between the sequences and the hybridization conditions such as temperature and salt concentration as earlier presented.
  • the region of identity is greater than about 5 bp, more preferably the region of identity is greater than 10 bp.
  • heterologous when used with respect to a nucleic acid (DNA or RNA) or protein refers to a nucleic acid or protein that does not occur naturally as part of the organism, cell, genome or DNA or RNA sequence in which it is present, or that is found in a cell or location or locations in the genome or DNA or RNA sequence that differ from that in which it is found in nature.
  • Heterologous nucleic acids or proteins are not endogenous to the cell into which it is introduced, but has been obtained from another cell or synthetically or recombinantly produced. Generally, though not necessarily, such nucleic acids encode proteins that are not normally produced by the cell in which the DNA is transcribed or expressed.
  • heterologous nucleic acids and proteins may also be referred to as foreign nucleic acids or proteins. Any nucleic acid or protein that one of skill in the art would recognize as heterologous or foreign to the cell in which it is expressed is herein encompassed by the term heterologous nucleic acid or protein.
  • heterologous also applies to non-natural combinations of nucleic acid or amino acid sequences, i.e. combinations where at least two of the combined sequences are foreign with respect to each other.
  • the cell of the invention that expresses araA, araB and araD is able to use L-arabinose and/or to convert it into L-ribulose, and/or xylulose 5-phosphate and/or a desired fermentation product as earlier defined herein and additionally exhibits the ability to use xylose and/or convert xylose into xylulose.
  • the conversion of xylose into xylulose is preferably a one step isomerisation step (direct isomerisation of xylose into xylulose). This type of cell is therefore able to use both L-arabinose and xylose.
  • “Using” xylose has preferably the same meaning as “using” L-arabinose as earlier defined herein.
  • Enzyme definitions are as used in WO 06/009434, for xylose isomerase (EC 5.3.1.5), xylulose kinase (EC 2.7.1.17), ribulose 5-phosphate epimerase (5.1.3.1), ribulose 5-phosphate isomerase (EC 5.3.1.6), transketolase (EC 2.2.1.1), transaldolase (EC 2.2.1.2), and aldose reductase” (EC 1.1.1.21).
  • the eukaryotic cell of the invention expressing araA, araB and araD as earlier defined herein has the ability of isomerising xylose to xylulose as e.g. described in WO 03/0624430 or in WO 06/009434.
  • the ability of isomerising xylose to xylulose is conferred to the host cell by transformation of the host cell with a nucleic acid construct comprising a nucleotide sequence encoding a xylose isomerase.
  • the transformed host cell's ability to isomerise xylose into xylulose is the direct isomerisation of xylose to xylulose.
  • the nucleotide sequence encodes a xylose isomerase that is preferably expressed in active form in the transformed host cell of the invention.
  • expression of the nucleotide sequence in the host cell produces a xylose isomerase with a specific activity of at least 10 U xylose isomerase activity per mg protein at 30° C., preferably at least 20, 25, 30, 50, 100, 200, 300 or 500 U per mg at 30° C.
  • the specific activity of the xylose isomerase expressed in the transformed host cell is herein defined as the amount of xylose isomerase activity units per mg protein of cell free lysate of the host cell, e.g. a yeast cell free lysate. Determination of the xylose isomerase activity has already been described earlier herein.
  • expression of the nucleotide sequence encoding the xylose isomerase in the host cell produces a xylose isomerase with a K m for xylose that is less than 50, 40, 30 or 25 mM, more preferably, the K m for xylose is about 20 mM or less.
  • a preferred nucleotide sequence encoding the xylose isomerase may be selected from the group consisting of:
  • the nucleotide sequence encoding the xylose isomerase may encode either a prokaryotic or an eukaryotic xylose isomerase, i.e. a xylose isomerase with an amino acid sequence that is identical to that of a xylose isomerase that naturally occurs in the prokaryotic or eukaryotic organism.
  • a xylose isomerase with an amino acid sequence that is identical to that of a xylose isomerase that naturally occurs in the prokaryotic or eukaryotic organism.
  • the present inventors have found that the ability of a particular xylose isomerase to confer to a eukaryotic host cell the ability to isomerise xylose into xylulose does not depend so much on whether the isomerase is of prokaryotic or eukaryotic origin.
  • a preferred nucleotide sequence encodes a xylose isomerase having an amino acid sequence that is related to the Piromyces sequence as defined above.
  • a preferred nucleotide sequence encodes a fungal xylose isomerase (e.g. from a Basidiomycete), more preferably a xylose isomerase from an anaerobic fungus, e.g.
  • a xylose isomerase from an anaerobic fungus that belongs to the families Neocallimastix, Caecomyces, Piromyces, Orpinomyces, or Ruminomyces.
  • a preferred nucleotide sequence encodes a bacterial xylose isomerase, preferably a Gram-negative bacterium, more preferably an isomerase from the class Bacteroides , or from the genus Bacteroides , most preferably from B. thetaiotaomicron (SEQ ID NO. 15).
  • the nucleotide sequence encoding the xylose isomerase may be adapted to optimise its codon usage to that of the eukaryotic host cell as earlier defined herein.
  • a host cell for transformation with the nucleotide sequence encoding the xylose isomerase as described above preferably is a host capable of active or passive xylose transport into the cell.
  • the host cell preferably contains active glycolysis.
  • the host cell may further contain an endogenous pentose phosphate pathway and may contain endogenous xylulose kinase activity so that xylulose isomerised from xylose may be metabolised to pyruvate.
  • the host further preferably contains enzymes for conversion of pyruvate to a desired fermentation product such as ethanol, lactic acid, 3-hydroxy-propionic acid, acrylic acid, acetic acid, succinic acid, citric acid, malic acid, fumaric acid, an amino acid, 1,3-propane-diol, ethylene, glycerol, butanol, a ⁇ -lactam antibiotic or a cephalosporin.
  • a preferred host cell is a host cell that is naturally capable of alcoholic fermentation, preferably, anaerobic alcoholic fermentation.
  • the host cell further preferably has a high tolerance to ethanol, a high tolerance to low pH (i.e.
  • a suitable cell is a eukaryotic microorganism like e.g. a fungus, however, most suitable as host cell are yeasts or filamentous fungi. Preferred yeasts and filamentous fungi have already been defined herein.
  • the cell of the invention is preferably transformed with a nucleic acid construct comprising the nucleotide sequence encoding the xylose isomerase.
  • the nucleic acid construct that is preferably used is the same as the one used comprising the nucleotide sequence encoding araA, araB or araD.
  • the cell of the invention in another preferred embodiment of the invention, the cell of the invention:
  • Genetic modifications that increase the flux of the pentose phosphate pathway may be introduced in the host cell in various ways. These including e.g. achieving higher steady state activity levels of xylulose kinase and/or one or more of the enzymes of the non-oxidative part pentose phosphate pathway and/or a reduced steady state level of unspecific aldose reductase activity. These changes in steady state activity levels may be effected by selection of mutants (spontaneous or induced by chemicals or radiation) and/or by recombinant DNA technology e.g. by overexpression or inactivation, respectively, of genes encoding the enzymes or factors regulating these genes.
  • the genetic modification comprises overexpression of at least one enzyme of the (non-oxidative part) pentose phosphate pathway.
  • the enzyme is selected from the group consisting of the enzymes encoding for ribulose-5-phosphate isomerase, ribulose-5-phosphate epimerase, transketolase and transaldolase, as described in WO 06/009434.
  • the enzymes that are overexpressed may be at least the enzymes ribulose-5-phosphate isomerase and ribulose-5-phosphate epimerase; or at least the enzymes ribulose-5-phosphate isomerase and transketolase; or at least the enzymes ribulose-5-phosphate isomerase and transaldolase; or at least the enzymes ribulose-5-phosphate epimerase and transketolase; or at least the enzymes ribulose-5-phosphate epimerase and transaldolase; or at least the enzymes transketolase and transaldolase; or at least the enzymes ribulose-5-phosphate epimerase, transketolase and transaldolase; or at least the enzymes ribulose-5-phosphate isomerase, transketolase and transaldolase; or at least the enzymes ribulose-5-phosphate isomerase, transketolase and transaldolase; or at least the enzymes ribulose-5-phosphate isomerase
  • each of the enzymes ribulose-5-phosphate isomerase, ribulose-5-phosphate epimerase, transketolase and transaldolase are overexpressed in the host cell. More preferred is a host cell in which the genetic modification comprises at least overexpression of both the enzymes transketolase and transaldolase as such a host cell is already capable of anaerobic growth on xylose. In fact, under some conditions we have found that host cells overexpressing only the transketolase and the transaldolase already have the same anaerobic growth rate on xylose as do host cells that overexpress all four of the enzymes, i.e.
  • ribulose-5-phosphate isomerase ribulose-5-phosphate epimerase
  • transketolase transaldolase
  • host cells overexpressing both of the enzymes ribulose-5-phosphate isomerase and ribulose-5-phosphate epimerase are preferred over host cells overexpressing only the isomerase or only the epimerase as overexpression of only one of these enzymes may produce metabolic imbalances.
  • an enzyme may be overexpressed by increasing the copy number of the gene coding for the enzyme in the host cell, e.g. by integrating additional copies of the gene in the host cell's genome, by expressing the gene from an episomal multicopy expression vector or by introducing a episomal expression vector that comprises multiple copies of the gene.
  • overexpression of enzymes in the host cells of the invention may be achieved by using a promoter that is not native to the sequence coding for the enzyme to be overexpressed, i.e. a promoter that is heterologous to the coding sequence to which it is operably linked. Suitable promoters to this end have already been defined herein.
  • the coding sequence used for overexpression of the enzymes preferably is homologous to the host cell of the invention. However, coding sequences that are heterologous to the host cell of the invention may likewise be applied, as mentioned in WO 06/009434.
  • a nucleotide sequence used for overexpression of ribulose-5-phosphate isomerase in the host cell of the invention is a nucleotide sequence encoding a polypeptide with ribulose-5-phosphate isomerase activity, whereby preferably the polypeptide has an amino acid sequence having at least 50, 60, 70, 80, 90 or 95% identity with SEQ ID NO. 17 or whereby the nucleotide sequence is capable of hybridising with the nucleotide sequence of SEQ ID NO. 18, under moderate conditions, preferably under stringent conditions.
  • a nucleotide sequence used for overexpression of ribulose-5-phosphate epimerase in the host cell of the invention is a nucleotide sequence encoding a polypeptide with ribulose-5-phosphate epimerase activity, whereby preferably the polypeptide has an amino acid sequence having at least 50, 60, 70, 80, 90 or 95% identity with SEQ ID NO. 19 or whereby the nucleotide sequence is capable of hybridising with the nucleotide sequence of SEQ ID NO. 20, under moderate conditions, preferably under stringent conditions.
  • a nucleotide sequence used for overexpression of transketolase in the host cell of the invention is a nucleotide sequence encoding a polypeptide with transketolase activity, whereby preferably the polypeptide has an amino acid sequence having at least 50, 60, 70, 80, 90 or 95% identity with SEQ ID NO. 21 or whereby the nucleotide sequence is capable of hybridising with the nucleotide sequence of SEQ ID NO. 22, under moderate conditions, preferably under stringent conditions.
  • a nucleotide sequence used for overexpression of transaldolase in the host cell of the invention is a nucleotide sequence encoding a polypeptide with transaldolase activity, whereby preferably the polypeptide has an amino acid sequence having at least 50, 60, 70, 80, 90 or 95% identity with SEQ ID NO. 23 or whereby the nucleotide sequence is capable of hybridising with the nucleotide sequence of SEQ ID NO. 24, under moderate conditions, preferably under stringent conditions.
  • Overexpression of an enzyme when referring to the production of the enzyme in a genetically modified host cell, means that the enzyme is produced at a higher level of specific enzymatic activity as compared to the unmodified host cell under identical conditions. Usually this means that the enzymatically active protein (or proteins in case of multi-subunit enzymes) is produced in greater amounts, or rather at a higher steady state level as compared to the unmodified host cell under identical conditions. Similarly this usually means that the mRNA coding for the enzymatically active protein is produced in greater amounts, or again rather at a higher steady state level as compared to the unmodified host cell under identical conditions.
  • Overexpression of an enzyme is thus preferably determined by measuring the level of the enzyme's specific activity in the host cell using appropriate enzyme assays as described herein.
  • overexpression of the enzyme may determined indirectly by quantifying the specific steady state level of enzyme protein, e.g. using antibodies specific for the enzyme, or by quantifying the specific steady level of the mRNA coding for the enzyme.
  • the latter may particularly be suitable for enzymes of the pentose phosphate pathway for which enzymatic assays are not easily feasible as substrates for the enzymes are not commercially available.
  • an enzyme to be overexpressed is overexpressed by at least a factor 1.1, 1.2, 1.5, 2, 5, 10 or 20 as compared to a strain which is genetically identical except for the genetic modification causing the overexpression. It is to be understood that these levels of overexpression may apply to the steady state level of the enzyme's activity, the steady state level of the enzyme's protein as well as to the steady state level of the transcript coding for the enzyme.
  • the host cell of the invention :
  • a particularly preferred xylulose kinase is a xylose kinase that is related to the xylulose kinase xylB from Piromyces as mentioned in WO 03/0624430.
  • a more preferred nucleotide sequence for use in overexpression of xylulose kinase in the host cell of the invention is a nucleotide sequence encoding a polypeptide with xylulose kinase activity, whereby preferably the polypeptide has an amino acid sequence having at least 45, 50, 55, 60, 65, 70, 80, 90 or 95% identity with SEQ ID NO. 27 or whereby the nucleotide sequence is capable of hybridising with the nucleotide sequence of SEQ ID NO. 28, under moderate conditions, preferably under stringent conditions.
  • genetic modification that increases the specific xylulose kinase activity may be combined with any of the modifications increasing the flux of the pentose phosphate pathway as described above, but this combination is not essential for the invention.
  • a host cell of the invention comprising a genetic modification that increases the specific xylulose kinase activity in addition to the expression of the araA, araB and araD enzymes as defined herein is specifically included in the invention.
  • the various means available in the art for achieving and analysing overexpression of a xylulose kinase in the host cells of the invention are the same as described above for enzymes of the pentose phosphate pathway.
  • a xylulose kinase to be overexpressed is overexpressed by at least a factor 1.1, 1.2, 1.5, 2, 5, 10 or 20 as compared to a strain which is genetically identical except for the genetic modification causing the overexpression. It is to be understood that these levels of overexpression may apply to the steady state level of the enzyme's activity, the steady state level of the enzyme's protein as well as to the steady state level of the transcript coding for the enzyme.
  • the host cell of the invention :
  • the expression of the araA, araB and araD enzymes as defined herein is combined with genetic modification that reduces unspecific aldose reductase activity.
  • the genetic modification leading to the reduction of unspecific aldose reductase activity may be combined with any of the modifications increasing the flux of the pentose phosphate pathway and/or with any of the modifications increasing the specific xylulose kinase activity in the host cells as described above, but these combinations are not essential for the invention.
  • a host cell expressing araA, araB, and araD, comprising an additional genetic modification that reduces unspecific aldose reductase activity is specifically included in the invention.
  • the host cell is CBS120327 deposited at the CBS Institute (The Netherlands) on Sep. 27, 2006.
  • the invention relates to modified host cells that are further adapted to L-arabinose (use L-arabinose and/or convert it into L-ribulose, and/or xylulose 5-phosphate and/or into a desired fermentation product and optionally xylose utilisation by selection of mutants, either spontaneous or induced (e.g. by radiation or chemicals), for growth on L-arabinose and optionally xylose, preferably on L-arabinose and optionally xylose as sole carbon source, and more preferably under anaerobic conditions. Selection of mutants may be performed by serial passaging of cultures as e.g. described by Kuyper et al. (2004, FEMS Yeast Res.
  • the cells are preferably cultured in the presence of approximately 20 g/l L-arabinose and/or approximately 20 g/l xylose.
  • the cell obtained at the end of this selection process is expected to be improved as to its capacities of using L-arabinose and/or xylose, and/or converting L-arabinose into L-ribulose and/or xylulose 5-phosphate and/or a desired fermentation product such as ethanol.
  • improved cell may mean that the obtained cell is able to use L-arabinose and/or xylose in a more efficient way than the cell it derives from.
  • the obtained cell is expected to better grow: increase of the specific growth rate of at least 2% than the cell it derives from under the same conditions.
  • the increase is of at least 4%, 6%, 8%, 10%, 15%, 20%, 25% or more.
  • the specific growth rate may be calculated from OD 660 as known to the skilled person. Therefore, by monitoring the OD 660 , one can deduce the specific growth rate.
  • “improved cell” may also mean that the obtained cell converts L-arabinose into L-ribulose and/or xylulose 5-phosphate and/or a desired fermentation product such as ethanol in a more efficient way than the cell it derives from.
  • the obtained cell is expected to produce higher amounts of L-ribulose and/or xylulose 5-phosphate and/or a desired fermentation product such as ethanol: increase of at least one of these compounds of at least 2% than the cell it derives from under the same conditions.
  • the increase is of at least 4%, 6%, 8%, 10%, 15%, 20%, 25% or more.
  • “improved cell” may also mean that the obtained cell converts xylose into xylulose and/or a desired fermentation product such as ethanol in a more efficient way than the cell it derives from.
  • the obtained cell is expected to produce higher amounts of xylulose and/or a desired fermentation product such as ethanol: increase of at least one of these compounds of at least 2% than the cell it derives from under the same conditions.
  • the increase is of at least 4%, 6%, 8%, 10%, 15%, 20%, 25% or more.
  • a preferred host cell of the invention at least one of the genetic modifications described above, including modifications obtained by selection of mutants, confer to the host cell the ability to grow on L-arabinose and optionally xylose as carbon source, preferably as sole carbon source, and preferably under anaerobic conditions.
  • the modified host cell produce essentially no xylitol, e.g. the xylitol produced is below the detection limit or e.g. less than 5, 2, 1, 0.5, or 0.3% of the carbon consumed on a molar basis.
  • the modified host cell has the ability to grow on L-arabinose and optionally xylose as sole carbon source at a rate of at least 0.001, 0.005, 0.01, 0.03, 0.05, 0.1, 0.2, 0.25 or 0.3 h ⁇ 1 under aerobic conditions, or, if applicable, at a rate of at least 0.001, 0.005, 0.01, 0.03, 0.05, 0.07, 0.08, 0.09, 0.1, 0.12, 0.15 or 0.2 h ⁇ 1 under anaerobic conditions
  • the modified host cell has the ability to grow on a mixture of glucose and L-arabinose and optionally xylose (in a 1:1 weight ratio) as sole carbon source at a rate of at least 0.001, 0.005, 0.01, 0.03, 0.05, 0.1, 0.2, 0.25 or 0.3 h ⁇ 1 under aerobic conditions, or, if applicable, at a rate of at least 0.001, 0.005, 0.01, 0.03, 0.05, 0.1, 0.12, 0.15, or
  • the modified host cell has a specific L-arabinose and optionally xylose consumption rate of at least 346, 350, 400, 500, 600, 650, 700, 750, 800, 900 or 1000 mg/g cells/h.
  • the modified host cell has a yield of fermentation product (such as ethanol) on L-arabinose and optionally xylose that is at least 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 80, 85, 90, 95 or 98% of the host cell's yield of fermentation product (such as ethanol) on glucose.
  • the modified host cell's yield of fermentation product (such as ethanol) on L-arabinose and optionally xylose is equal to the host cell's yield of fermentation product (such as ethanol) on glucose.
  • the modified host cell's biomass yield on L-arabinose and optionally xylose is preferably at least 55, 60, 70, 80, 85, 90, 95 or 98% of the host cell's biomass yield on glucose. More preferably, the modified host cell's biomass yield on L-arabinose and optionally xylose is equal to the host cell's biomass yield on glucose. It is understood that in the comparison of yields on glucose and L-arabinose and optionally xylose both yields are compared under aerobic conditions or both under anaerobic conditions.
  • the host cell is CBS120328 deposited at the CBS Institute (The Netherlands) on Sep. 27, 2006 or CBS121879 deposited at the CBS Institute (The Netherlands) on Sep. 20, 2007.
  • the cell expresses one or more enzymes that confer to the cell the ability to produce at least one fermentation product selected from the group consisting of ethanol, lactic acid, 3-hydroxy-propionic acid, acrylic acid, acetic acid, succinic acid, citric acid, malic acid, fumaric acid, an amino acid, 1,3-propane-diol, ethylene, glycerol, butanol, a ⁇ -lactam antibiotic and a cephalosporin.
  • the host cell of the invention is a host cell for the production of ethanol.
  • the invention relates to a transformed host cell for the production of fermentation products other than ethanol.
  • Such non-ethanolic fermentation products include in principle any bulk or fine chemical that is producible by a eukaryotic microorganism such as a yeast or a filamentous fungus.
  • Such fermentation products include e.g. lactic acid, 3-hydroxy-propionic acid, acrylic acid, acetic acid, succinic acid, citric acid, malic acid, fumaric acid, an amino acid, 1,3-propane-diol, ethylene, glycerol, butanol, a ⁇ -lactam antibiotic and a cephalosporin.
  • a preferred host cell of the invention for production of non-ethanolic fermentation products is a host cell that contains a genetic modification that results in decreased alcohol dehydrogenase activity.
  • the invention relates to fermentation processes in which a host cell of the invention is used for the fermentation of a carbon source comprising a source of L-arabinose and optionally a source of xylose.
  • a carbon source comprising a source of L-arabinose and optionally a source of xylose.
  • the source of L-arabinose and the source of xylose are L-arabinose and xylose.
  • the carbon source in the fermentation medium may also comprise a source of glucose.
  • the source of L-arabinose, xylose or glucose may be L-arabinose, xylose or glucose as such or may be any carbohydrate oligo- or polymer comprising L-arabinose, xylose or glucose units, such as e.g.
  • carbohydrases such as xylanases, glucanases, amylases and the like
  • carbohydrases may be added to the fermentation medium or may be produced by the modified host cell.
  • the modified host cell may be genetically engineered to produce and excrete such carbohydrases.
  • the modified host cell ferments both the L-arabinose (optionally xylose) and glucose, preferably simultaneously in which case preferably a modified host cell is used which is insensitive to glucose repression to prevent diauxic growth.
  • the fermentation medium will further comprise the appropriate ingredient required for growth of the modified host cell. Compositions of fermentation media for growth of microorganisms such as yeasts or filamentous fungi are well known in the art.
  • a process for producing a fermentation product selected from the group consisting of ethanol, lactic acid, 3-hydroxy-propionic acid, acrylic acid, acetic acid, succinic acid, citric acid, malic acid, fumaric acid, an amino acid, 1,3-propane-diol, ethylene, glycerol, butanol, a ⁇ -lactam antibiotic and a cephalosporin whereby the process comprises the steps of:
  • the fermentation process is a process for the production of a fermentation product such as e.g. ethanol, lactic acid, 3-hydroxy-propionic acid, acrylic acid, acetic acid, succinic acid, citric acid, malic acid, fumaric acid, an amino acid, 1,3-propane-diol, ethylene, glycerol, butanol, a ⁇ -lactam antibiotic, such as Penicillin G or Penicillin V and fermentative derivatives thereof, and/or a cephalosporin.
  • the fermentation process may be an aerobic or an anaerobic fermentation process.
  • An anaerobic fermentation process is herein defined as a fermentation process run in the absence of oxygen or in which substantially no oxygen is consumed, preferably less than 5, 2.5 or 1 mmol/L/h, more preferably 0 mmol/L/h is consumed (i.e. oxygen consumption is not detectable), and wherein organic molecules serve as both electron donor and electron acceptors.
  • substantially no oxygen preferably less than 5, 2.5 or 1 mmol/L/h, more preferably 0 mmol/L/h is consumed (i.e. oxygen consumption is not detectable)
  • organic molecules serve as both electron donor and electron acceptors.
  • NADH produced in glycolysis and biomass formation cannot be oxidised by oxidative phosphorylation.
  • pyruvate or one of its derivatives as an electron and hydrogen acceptor thereby regenerating NAD + .
  • pyruvate is used as an electron (and hydrogen acceptor) and is reduced to fermentation products such as ethanol, lactic acid, 3-hydroxy-propionic acid, acrylic acid, acetic acid, succinic acid, citric acid, malic acid, fumaric acid, an amino acid, 1,3-propane-diol, ethylene, glycerol, butanol, a ⁇ -lactam antibiotics and a cephalosporin.
  • the fermentation process is anaerobic.
  • An anaerobic process is advantageous since it is cheaper than aerobic processes: less special equipment is needed. Furthermore, anaerobic processes are expected to give a higher product yield than aerobic processes.
  • the process of the invention is the first anaerobic fermentation process with a medium comprising a source of L-arabinose that has been developed so far.
  • the fermentation process is under oxygen-limited conditions. More preferably, the fermentation process is aerobic and under oxygen-limited conditions.
  • An oxygen-limited fermentation process is a process in which the oxygen consumption is limited by the oxygen transfer from the gas to the liquid. The degree of oxygen limitation is determined by the amount and composition of the ingoing gasflow as well as the actual mixing/mass transfer properties of the fermentation equipment used.
  • the rate of oxygen consumption is at least 5.5, more preferably at least 6 and even more preferably at least 7 mmol/L/h.
  • the fermentation process is preferably run at a temperature that is optimal for the modified cell.
  • the fermentation process is performed at a temperature which is less than 42° C., preferably less than 38° C.
  • the fermentation process is preferably performed at a temperature which is lower than 35, 33, 30 or 28° C. and at a temperature which is higher than 20, 22, or 25° C.
  • a preferred process is a process for the production of ethanol, whereby the process comprises the steps of: (a) fermenting a medium containing a source of L-arabinose and optionally xylose with a modified host cell as defined herein, whereby the host cell ferments L-arabinose and optionally xylose to ethanol; and optionally, (b) recovery of the ethanol.
  • the fermentation medium may also comprise a source of glucose that is also fermented to ethanol.
  • the fermentation process for the production of ethanol is anaerobic. Anaerobic has already been defined earlier herein.
  • the fermentation process for the production of ethanol is aerobic.
  • the fermentation process for the production of ethanol is under oxygen-limited conditions, more preferably aerobic and under oxygen-limited conditions. Oxygen-limited conditions have already been defined earlier herein.
  • the volumetric ethanol productivity is preferably at least 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 5.0 or 10.0 g ethanol per litre per hour.
  • the ethanol yield on L-arabinose and optionally xylose and/or glucose in the process preferably is at least 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 95 or 98%.
  • the ethanol yield is herein defined as a percentage of the theoretical maximum yield, which, for glucose and L-arabinose and optionally xylose is 0.51 g. ethanol per g. glucose or xylose.
  • the invention relates to a process for producing a fermentation product selected from the group consisting of lactic acid, 3-hydroxy-propionic acid, acrylic acid, acetic acid, succinic acid, citric acid, malic acid, fumaric acid, an amino acid, 1,3-propane-diol, ethylene, glycerol, butanol, a ⁇ -lactam antibiotic and a cephalosporin.
  • the process preferably comprises the steps of (a) fermenting a medium containing a source of L-arabinose and optionally xylose with a modified host cell as defined herein above, whereby the host cell ferments L-arabinose and optionally xylose to the fermentation product, and optionally, (b) recovery of the fermentation product.
  • the medium also contains a source of glucose.
  • another fermentation process is provided as a further aspect of the invention wherein, at least two distinct cells are used for the fermentation of a carbon source comprising at least two sources of carbon selected from the group consisting of but not limited thereto: a source of L-arabinose, a source of xylose and a source of glucose.
  • a carbon source comprising at least two sources of carbon selected from the group consisting of but not limited thereto: a source of L-arabinose, a source of xylose and a source of glucose.
  • “at least two distinct cells” means this process is preferably a co-fermentation process.
  • two distinct cells are used: one being the one of the invention as earlier defined able to use L-arabinose, and/or to convert it into L-ribulose, and/or xylulose 5-phosphate and/or into a desired fermentation product such as ethanol and optionally being able to use xylose, the other one being for example a strain which is able to use xylose and/or convert it into a desired fermentation product such as ethanol as defined in WO 03/062430 and/or WO 06/009434.
  • a cell which is able to use xylose is preferably a strain which exhibits the ability of directly isomerising xylose into xylulose (in one step) as earlier defined herein.
  • These two distinct strains are preferably cultived in the presence of a source of L-arabinose, a source of xylose and optionally a source of glucose.
  • Three distinct cells or more may be co-cultivated and/or three or more sources of carbon may be used, provided at least one cell is able to use at least one source of carbon present and/or to convert it into a desired fermentation product such as ethanol.
  • the expression “use at least one source of carbon” has the same meaning as the expression “use of L-arabinose”.
  • the expression “convert it (i.e. a source of carbon) into a desired fermentation product has the same meaning as the expression “convert L-arabinose into a desired fermentation product”.
  • the invention relates to a process for producing a fermentation product selected from the group consisting of ethanol, lactic acid, 3-hydroxy-propionic acid, acrylic acid, acetic acid, succinic acid, citric acid, malic acid, fumaric acid, amino acids, 1,3-propane-diol, ethylene, glycerol, butanol, ⁇ -lactam antibiotics and cephalosporins, whereby the process comprises the steps of:
  • host cells are transformed with the various nucleic acid constructs of the invention by methods well known in the art.
  • methods are e.g. known from standard handbooks, such as Sambrook and Russel (2001) “Molecular Cloning: A Laboratory Manual (3 rd edition), Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, or F. Ausubel et al, eds., “Current protocols in molecular biology”, Green Publishing and Wiley Interscience, New York (1987).
  • Methods for transformation and genetic modification of fungal host cells are known from e.g. EP-A-0 635 574, WO 98/46772, WO 99/60102 and WO 00/37671.
  • the 3′-end of the nucleotide acid sequence encoding the enzyme(s) preferably is operably linked to a transcription terminator sequence.
  • the terminator sequence is operable in a host cell of choice, such as e.g. the yeast species of choice. In any case the choice of the terminator is not critical; it may e.g. be from any yeast gene, although terminators may sometimes work if from a non-yeast, eukaryotic, gene.
  • the transcription termination sequence further preferably comprises a polyadenylation signal.
  • Preferred terminator sequences are the alcohol dehydrogenase (ADH1) and the PGI1 terminators. More preferably, the ADH1 and the PGI1 terminators are both from S. cerevisiae (SEQ ID NO:50 and SEQ ID NO:53 respectively).
  • a selectable marker may be present in the nucleic acid construct.
  • the term “marker” refers to a gene encoding a trait or a phenotype which permits the selection of, or the screening for, a host cell containing the marker.
  • the marker gene may be an antibiotic resistance gene whereby the appropriate antibiotic can be used to select for transformed cells from among cells that are not transformed.
  • non-antibiotic resistance markers are used, such as auxotrophic markers (URA3, TRP1, LEU).
  • the host cells transformed with the nucleic acid constructs are marker gene free.
  • recombinant marker gene free microbial host cells are disclosed in EP-A-0 635 574 and are based on the use of bidirectional markers.
  • a screenable marker such as Green Fluorescent Protein, lacZ, luciferase, chloramphenicol acetyltransferase, beta-glucuronidase may be incorporated into the nucleic acid constructs of the invention allowing to screen for transformed cells.
  • nucleic acid constructs of the invention include, but are not limited to, one or more leader sequences, enhancers, integration factors, and/or reporter genes, intron sequences, centromers, telomers and/or matrix attachment (MAR) sequences.
  • the nucleic acid constructs of the invention may further comprise a sequence for autonomous replication, such as an ARS sequence.
  • Suitable episomal nucleic acid constructs may e.g. be based on the yeast 2 ⁇ or pKD1 (Fleer et al., 1991, Biotechnology 9:968-975) plasmids.
  • the nucleic acid construct may comprise sequences for integration, preferably by homologous recombination.
  • sequences may thus be sequences homologous to the target site for integration in the host cell's genome.
  • the nucleic acid constructs of the invention can be provided in a manner known per se, which generally involves techniques such as restricting and linking nucleic acids/nucleic acid sequences, for which reference is made to the standard handbooks, such as Sambrook and Russel (2001) “Molecular Cloning: A Laboratory Manual (3 rd edition), Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press.
  • the L-arabinose consuming Sachharomyces cerevisiae strain described in this work is based on strain RWB220, which is itself a derivative of RWB217.
  • RWB217 is a CEN.PK strain in which four genes coding for the expression of enzymes in the pentose phosphate pathway have been overexpressed, TAL1, TKL1, RPE1, RKI1 (Kuyper et al., 2005a).
  • GRE3 aldose reductase
  • Strain RWB217 also contains two plasmids, a single copy plasmid with a LEU2 marker for overexpression of the xylulokinase (XKS1) and an episomal, multicopy plasmid with URA3 as the marker for the expression of the xylose isomerase, XylA.
  • RWB217 was subjected to a selection procedure for improved growth on xylose which is described in Kuyper et al. (2005b). The procedure resulted in two pure strains, RWB218 (Kuyper et al., 2005b) and RWB219.
  • the difference between RWB218 and RWB219 is that after the selection procedure, RWB218 was obtained by plating and restreaking on mineral medium with glucose as the carbon source, while for RWB219 xylose was used.
  • Strain RWB219 was grown non-selectively on YP with glucose (YPD) as the carbon source in order to facilitate the loss of both plasmids. After plating on YPD single colonies were tested for plasmid loss by looking at uracil and leucine auxotrophy. A strain that had lost both plasmids was transformed with pSH47, containing the cre recombinase, in order to remove a KanMX cassette (Guldener et al., 1996), still present after integrating the RKI1 overexpression construct.
  • YPD glucose
  • Yeast Peptone medium (10 g/l yeast extract and 20 g/l peptone both from BD Difco Belgium) with 1% galactose and incubated for 1 hour at 30° C. About 200 cells were plated on YPD. The resulting colonies were checked for loss of the KanMX marker (G418 resistance) and pSH47 (URA3). A strain that had lost both the KanMX marker and the pSH47 plasmid was then named RWB220. To obtain the strain tested in this patent, RWB220 was transformed with pRW231 and pRW243 (table 2), resulting in strain IMS0001.
  • yeast In order to grow on L-arabinose, yeast needs to express three different genes, an L-arabinose isomerase (AraA), a L-ribulokinase (AraB), and a L-ribulose-5-P 4-epimerase (AraD) (Becker and Boles, 2003).
  • AraA L-arabinose isomerase
  • AraB L-ribulokinase
  • AraD L-ribulose-5-P 4-epimerase
  • the L. plantarum AraA and AraD genes were ligated into plasmid pAKX002, the 2 ⁇ XylA bearing plasmid.
  • the AraA cassette was constructed by amplifying a truncated version of the TDH3 promoter with SpeI5′Ptdh3 and 5′AraAPtdh3 (SEQ ID NO: 49), the AraA gene with Ptdh5′AraA and Tadh3′AraA and the ADH1 terminator (SEQ ID NO:50) with 3′AraATadh1 and 3′Tadh1-SpeI. The three fragments were extracted from gel and mixed in roughly equimolar amounts. On this mixture a PCR was performed using the SpeI-5′Ptdh3 and 3′Tadh1SpeI oligos.
  • the resulting P TDH3 -AraA-T ADH1 cassette was gel purified, cut at the 5′ and 3 ′ SpeI sites and then ligated into pAKX002 cut with NheI, resulting in plasmid pRW230.
  • the AraD construct was made by first amplifying a truncated version of the HXT7 promoter (SEQ ID NO:52) with oligos SalI5′Phxt7 and 5′AraDPhxt, the AraD gene with Phxt5′AraD and Tpgi3′AraD and the GPI1 terminator (SEQ ID NO:53) region with the 3′AraDTpgi and 3′TpgiSalI oligos. The resulting fragments were extracted from gel and mixed in roughly equimolar amounts, after which a PCR was performed using the SalI5′Phxt7 and 3′Tpgi1SalI oligos.
  • the resulting P HXT7 -AraD-T PGI1 cassette was gel purified, cut at the 5′ and 3′ SalI sites and then ligated into pRW230 cut with XhoI, resulting in plasmid pRW231 ( FIG. 1 ).
  • p415ADHXKS (Kuyper et al., 2005a) was first changed into pRW229, by cutting both p415ADHXKS and pRS305 with PvuI and ligating the ADHXKS-containing PvuI fragment from p415ADHXKS to the vector backbone from pRS305, resulting in pRW229.
  • a cassette, containing the L. plantarum AraB gene between the PGI1 promoter (SEQ ID NO:51) and ADH1 terminator (SEQ ID NO:50) was made by amplifying the PGI1 promoter with the SacI5′Ppgi1 and 5′AraBPpgi1 oligos, the AraB gene with the Ppgi5′AraB and Tadh3′AraB oligos and the ADH1 terminator with 3′AraBTadh1 and 3′Tadh1SacI oligos.
  • the three fragments were extracted from gel and mixed in roughly equimolar amounts.
  • Strain RWB220 was transformed with pRW231 and pRW243 (table 2), resulting in strain IMS0001.
  • Amplification of the (elements of the) AraA, AraB and AraD cassettes was done with Vent R DNA polymerase (New England Biolabs) according to the manufacturer's specification.
  • the template was chromosomal DNA of S. cerevisiae CEN.PK113-7D for the promoters and terminators, or Lactobacillus plantarum DSM20205 for the Ara genes.
  • the polymerase chain reaction (PCR) was performed in a Biometra TGradient Thermocycler (Biometra, Gottingen, Germany) with the following settings: 30 cycles of 1 min annealing at 55° C., 60° C. or 65° C., 1 to 3 min extension at 75° C., depending on expected fragment size, and 1 min denaturing at 94° C.
  • Shake-flask cultivations were performed at 30° C. in a synthetic medium (Verduyn et al., 1992). The pH of the medium was adjusted to 6.0 with 2 M KOH prior to sterilisation. For solid synthetic medium, 1.5% of agar was added.
  • Pre-cultures were prepared by inoculating 100 ml medium containing the appropriate sugar in a 500-ml shake flask with a frozen stock culture. After incubation at 30° C. in an orbital shaker (200 rpm), this culture was used to inoculate either shake-flask cultures or fermenter cultures.
  • the synthetic medium for anaerobic cultivation was supplemented with 0.01 g l ⁇ 1 ergosterol and 0.42 g Tween 80 dissolved in ethanol (Andreasen and Stier, 1953; Andreasen and Stier, 1954). Anaerobic (sequencing) batch cultivation was carried out at 30° C.
  • Exhaust gas was cooled in a condensor (2° C.) and dried with a Permapure dryer type MD-110-48P-4 (Permapure, Toms River, USA). O2 and CO2 concentrations were determined with a NGA 2000 analyser (Rosemount Analytical, Orrville, USA). Exhaust gasflow rate and specific oxygen-consumption and carbondioxide production rates were determined as described previously (Van Urk et al., 1988; Weusthuis et al., 1994). In calculating these biomass-specific rates, volume changes caused by withdrawing culture samples were taken account for.
  • Glucose, xylose, arabinose, xylitol, organic acids, glycerol and ethanol were analysed by HPLC using a Waters Alliance 2690 HPLC (Waters, Milford, USA) supplied with a BioRad HPX 87H column (BioRad, Hercules, USA), a Waters 2410 refractive-index detector and aWaters 2487 UV detector.
  • the column was eluted at 60° C. with 0.5 g l ⁇ 1 sulphuric acid at a flow rate of 0.6 ml min ⁇ 1 .
  • a 50% NaOH solution with low carbonate concentration (Baker Analysed, Deventer, The Netherlands) was used instead of NaOH pellets.
  • the eluents were degassed with Helium (He) for 30 min and then kept under a He atmosphere.
  • He Helium
  • the gradient pump was programmed to generate the following gradients: 100% A and 0% B (0 min), a linear decrease of A to 70% and a linear increase of B to 30% (0-30 min), a linear decrease of A to 30% and a linear increase of B to 70% (30-70 min), a linear decrease of A to 0% and a linear increase of B to 100% (70-75 min), 0% A and 100% B (75-85 min), a linear increase of A to 100% and a linear decrease of B to 0% (85-95 min).
  • the mobile phase was run at a flow rate of 1 ml/min. Other conditions were according to Smits et al. (1998).
  • Carbon recoveries were calculated as carbon in products formed, divided by the total amount of sugar carbon consumed, and were based on a carbon content of biomass of 48%. To correct for ethanol evaporation during the fermentations, the amount of ethanol produced was assumed to be equal to the measured cumulative production of CO 2 minus the CO 2 production that occurred due to biomass synthesis (5.85 mmol CO 2 per gram biomass (Verduyn et al., 1990)) and the CO 2 associated with acetate formation.
  • Strain IMS0001 (CBS120327 deposited at the CBS on 27/1506), containing the genes encoding the pathways for both xylose (XylA and XKS1) and arabinose (AraA, AraB, AraD) metabolization, was constructed according the procedure described above. Although capable of growing on xylose (data not shown), strain IMS0001 did not seem to be capable of growing on solid synthetic medium supplemented with 2% L-arabinose. Mutants of IMS0001 capable of utilizing L-arabinose as carbon source for growth were selected by serial transfer in shake flasks and by sequencing-batch cultivation in fermenters (SBR).
  • SBR sequencing-batch cultivation in fermenters
  • this culture was transferred at an OD 660 of 1.7 to a shake flask containing 2% arabinose. Cultures were then sequentially transferred to fresh medium containing 2% arabinose at an OD 660 of 2-3. Utilization of arabinose was confirmed by occasionally measuring arabinose concentrations by HPLC (data not shown). The growth rate of these cultures increased from 0 to 0.15 h ⁇ 1 in approximately 3600 hours ( FIG. 3 ).
  • a batch fermentation under oxygen limited conditions was started by inoculating 1 l of synthetic medium supplemented with 2% of arabinose with a 100 ml shake flask culture of arabinose-grown IMS0001 cells with a maximum growth rate on 2% of L-arabinose of approximately 0.12 h ⁇ 1 .
  • the culture was subjected to anaerobic conditions by sparging with nitrogen gas.
  • the sequential cycles of anaerobic batch cultivation were started by either manual or automated replacement of 90% of the culture with synthetic medium with 20 g l ⁇ 1 arabinose. For each cycle during the SBR fermentation, the exponential growth rate was estimated from the CO 2 profile ( FIG. 4 ).
  • Biomass hydrolysates a desired feedstock for industrial biotechnology, contain complex mixtures consisting of various sugars amongst which glucose, xylose and arabinose are commonly present in significant fractions.
  • an anaerobic batch fermentation was performed with a mixed culture of the arabinose-fermenting strain IMS0002, and the xylose-fermenting strain RWB218.
  • An anaerobic batch fermenter containing 800 ml of synthetic medium supplied with 30 g l ⁇ 1 D-glucose, 15 g l ⁇ 1 D -xylose, and 15 g l ⁇ 1 L-arabinose was inoculated with 100 ml of pre-culture of strain IMS0002. After 10 hours, a 100 ml inoculum of RWB218 was added. In contrast to the mixed sugar fermentation with only strain IMS0002, both xylose and arabinose were consumed after glucose depletion ( FIG. 5D ).
  • the mixed culture completely consumed all sugars, and within 80 hours 564.0 ⁇ 6.3 mmol 1 1 ethanol (calculated from the CO 2 production) was produced with a high overall yield of 0.42 g g ⁇ 1 sugar.
  • Xylitol was produced only in small amounts, to a concentration of 4.7 mmol l ⁇ 1 .
  • strain IMS0002 was determined during anaerobic batch fermentations on synthetic medium with either L-arabinose as the sole carbon source, or a mixture of glucose, xylose and L-arabinose.
  • the pre-cultures for these anaerobic batch fermentations were prepared in shake flasks containing 100 ml of synthetic medium with 2% L-arabinose, by inoculating with ⁇ 80° C. frozen stocks of strain IMS0002, and incubating for 48 hours at 30° C.
  • FIG. 5A shows that strain IMS0002 is capable of fermenting 20 g l ⁇ 1 L-arabinose to ethanol during an anaerobic batch fermentation of approximately 70 hours.
  • the specific growth rate under anaerobic conditions with L-arabinose as sole carbon source was 0.05 ⁇ 0.001 h ⁇ 1 .
  • the ethanol yield from 20 g l ⁇ 1 arabinose was 0.43 ⁇ 0.003 g g ⁇ 1 . Without evaporation correction the ethanol yield was 0.35 ⁇ 0.01 g g ⁇ 1 of arabinose. No formation of arabinitol was observed during anaerobic growth on arabinose.
  • FIG. 5A shows that strain IMS0002 is capable of fermenting 20 g l ⁇ 1 L-arabinose to ethanol during an anaerobic batch fermentation of approximately 70 hours.
  • the specific growth rate under anaerobic conditions with L-arabinose as sole carbon source was 0.05 ⁇ 0.001 h ⁇ 1 .
  • FIG. 5C the fermentation profile of a mixture of 30 g l ⁇ 1 glucose, 15 g l ⁇ 1 D-xylose, and 15 g l ⁇ 1 L-arabinose by strain IMS0002 is shown.
  • Arabinose consumption started after glucose depletion. Within 80 hours, both the glucose and arabinose were completely consumed. Only 20 mM from 100 mM of xylose was consumed by strain IMS0002. In addition, the formation of 20 mM of xylitol was observed. Apparently, the xylose was converted into xylitol by strain IMS0002.
  • the ethanol yield from the total of sugars was lower than for the above described fermentations: 0.38 ⁇ 0.001 g g ⁇ 1 .
  • the ethanol yield from the total of glucose and arabinose was similar to the other fermentations: 0.43 ⁇ 0.001 g g ⁇ 1 .
  • Table 1 shows the arabinose consumption rates and the ethanol production rates observed for the anaerobic batch fermentation of strain IMS0002.
  • Arabinose was consumed with a rate of 0.23-0.75 g h ⁇ 1 g ⁇ 1 biomass dry weight.
  • the rate of ethanol produced from arabinose varied from 0.08-0.31 g h ⁇ 1 g ⁇ 1 biomass dry weight.
  • strain IMS0001 was able to ferment xylose (data not shown).
  • the selected strain IMS0002 was not capable of fermenting xylose to ethanol ( FIG. 5C ).
  • a colony of strain IMS0002 was transferred to solid synthetic medium with 2% of D-xylose, and incubated in an anaerobic jar at 30° C. for 25 days. Subsequently, a colony was again transferred to solid synthetic medium with 2% of arabinose. After 4 days of incubation at 30° C., a colony was transferred to a shake flask containing synthetic medium with 2% arabinose. After incubation at 30° C.
  • strain IMS0001 was able to ferment xylose (data not shown).
  • the selected strain IMS0002 was not capable of fermenting xylose to ethanol ( FIG. 5C ).
  • a colony of strain IMS0002 was transferred to solid synthetic medium with 2% of D-xylose, and incubated in an anaerobic jar at 30° C. for 25 days. Subsequently, a colony was again transferred to solid synthetic medium with 2% of arabinose. After 4 days of incubation at 30° C., a colony was transferred to a shake flask containing synthetic medium with 2% arabinose. After incubation at 30° C. for 6 days, 30% of glycerol was added, samples were taken and stored at ⁇ 80° C.
  • strain IMS0003 was determined during an anaerobic batch fermentation on synthetic medium with a mixture of 30 g l ⁇ 1 glucose, 15 g l ⁇ 1 D-xylose and 15 g l ⁇ 1 L-arabinose.
  • the pre-culture for this anaerobic batch fermentation was prepared in a shake flasks containing 100 ml of synthetic medium with 2% L-arabinose, by inoculating with a ⁇ 80° C. frozen stock of strain IMS0003, and incubated for 48 hours at 30° C.
  • FIG. 7 the fermentation profile of a mixture of 30 g l ⁇ 1 glucose, 15 g l ⁇ 1 D-xylose, and 15 g l ⁇ 1 L-arabinose by strain IMS0003 is shown.
  • Arabinose consumption started after glucose depletion. Within 70 hours, the glucose, xylose and arabinose were completely consumed. Xylose and arabinose were consumed simultaneously. At least 406 mM of ethanol was produced from the total of sugars, not taking into account the evaporation of the ethanol. The final ethanol concentration calculated from the cumulative CO 2 production was 572 mmol l ⁇ 1 , corresponding to an ethanol yield of 0.46 g g ⁇ 1 of total sugar.
  • strain IMS0003 did not produce detectable amounts of xylitol.
  • Plasmids used plasmid characteristics Reference pRS305 Integration, LEU2 Gietz and Sugino, 1988 pAKX002 2 ⁇ , URA3, P TPIl -Piromyces xylA Kuyper et al.
US12/442,013 2006-10-02 2007-10-01 Metabolic engineering of arabinose-fermenting yeast cells Abandoned US20100086965A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/442,013 US20100086965A1 (en) 2006-10-02 2007-10-01 Metabolic engineering of arabinose-fermenting yeast cells

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US84835706P 2006-10-02 2006-10-02
EP06121633.9 2006-10-02
EP06121633 2006-10-02
PCT/NL2007/000246 WO2008041840A1 (fr) 2006-10-02 2007-10-01 Génie métabolique de cellules de levure induisant la fermentation de l'arabinose
US12/442,013 US20100086965A1 (en) 2006-10-02 2007-10-01 Metabolic engineering of arabinose-fermenting yeast cells

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2007/000246 A-371-Of-International WO2008041840A1 (fr) 2006-10-02 2007-10-01 Génie métabolique de cellules de levure induisant la fermentation de l'arabinose

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/345,146 Continuation US9303253B2 (en) 2006-10-02 2012-01-06 Metabolic engineering of arabinose-fermenting yeast cells

Publications (1)

Publication Number Publication Date
US20100086965A1 true US20100086965A1 (en) 2010-04-08

Family

ID=38800716

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/442,013 Abandoned US20100086965A1 (en) 2006-10-02 2007-10-01 Metabolic engineering of arabinose-fermenting yeast cells
US13/345,146 Active 2028-08-04 US9303253B2 (en) 2006-10-02 2012-01-06 Metabolic engineering of arabinose-fermenting yeast cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/345,146 Active 2028-08-04 US9303253B2 (en) 2006-10-02 2012-01-06 Metabolic engineering of arabinose-fermenting yeast cells

Country Status (8)

Country Link
US (2) US20100086965A1 (fr)
EP (1) EP2069476B1 (fr)
JP (2) JP5553433B2 (fr)
AU (1) AU2007302867B2 (fr)
CA (1) CA2664646C (fr)
EA (1) EA016303B1 (fr)
MX (1) MX2009003501A (fr)
WO (1) WO2008041840A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110104736A1 (en) * 2008-03-13 2011-05-05 Jacobus Thomas Pronk Selection of organisms capable of fermenting mixed substrates
WO2012009272A2 (fr) * 2010-07-14 2012-01-19 Codexis, Inc. Fermentation de pentose par un micro-organisme recombinant
US20130035515A1 (en) * 2011-06-17 2013-02-07 Butamax(Tm) Advanced Biofuels Llc Lignocellulosic hydrolysates as feedstocks for isobutanol fermentation
WO2013071112A1 (fr) * 2011-11-10 2013-05-16 Mascoma Corporation Souche génétiquement modifiée de s. cerevisiae conçue pour fermenter le xylose et l'arabinose
US20140141473A1 (en) * 2011-04-22 2014-05-22 Dsm Ip Assets B.V. Yeast cell capable of converting sugars including arabinose and xlose
US9551015B2 (en) 2009-07-10 2017-01-24 Dsm Ip Assets B.V. Fermentative production of ethanol from glucose, galactose and arabinose employing a recombinant yeast strain
EP2561064B1 (fr) 2010-04-21 2017-10-18 DSM IP Assets B.V. Cellule adaptée à la fermentation d' une composition de sucres mixtes
US10689670B2 (en) 2016-06-14 2020-06-23 Dsm Ip Assets B.V. Recombinant yeast cell
US11421256B2 (en) 2009-10-08 2022-08-23 Dsm Ip Assets B.V. Process for enzymatic hydrolysis of lignocellulosic material and fermentation of sugars

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008153676A2 (fr) * 2007-05-21 2008-12-18 The Regents Of The University Of California Séquences nucléotiques codant pour les enzymes de fermentation et de la voie du pentose phosphate présentant une cinétique translationnelle plus fine et procédés de réalisation correspondants
EP2250262B1 (fr) * 2008-03-07 2015-07-29 DSM IP Assets B.V. Cellule de fermentation de sucre pentose
GB0812318D0 (en) 2008-07-04 2008-08-13 Terranol As Microorganism
WO2010014817A2 (fr) * 2008-07-30 2010-02-04 Novozymes A/S Élaboration de produits de fermentation
ES2672348T3 (es) * 2008-12-24 2018-06-14 Dsm Ip Assets B.V. Genes de la isomerasa de xilosa y su uso en la fermentación de azúcares pentosas
WO2011079388A1 (fr) 2009-12-30 2011-07-07 Iogen Energy Corporation Souches de levure modifiées présentant une fermentation accrue d'hydrolysats lignocellulosiques
US8709770B2 (en) 2010-08-31 2014-04-29 Iogen Energy Corporation Process for improving the hydrolysis of cellulose in high consistency systems using one or more unmixed and mixed hydrolysis reactors
KR101246780B1 (ko) * 2010-10-06 2013-03-26 한국과학기술원 아라비노스 대사경로가 도입된 자일리톨 생산균주 및 이를 이용한 자일리톨 생산방법
BR112013008981A2 (pt) 2010-10-13 2017-10-03 Dsm Ip Assets Bv Célula de levedura que fermenta pentose e glicose
FR2968313B1 (fr) 2010-12-03 2014-10-10 Lesaffre & Cie Procede de preparation d'une levure industrielle, levure industrielle et application a la production d'ethanol a partir d'au moins un pentose
NL2008682C2 (en) 2012-04-23 2013-10-31 Stichting Energie Wet biomass treatment.
WO2014033019A1 (fr) 2012-08-28 2014-03-06 Dsm Ip Assets B.V. Souches de levures modifiées pour produire de l'éthanol à partir d'acétate
IN2015DN01041A (fr) 2012-08-28 2015-06-26 Dsm Ip Assets Bv
EP2909305B1 (fr) 2012-10-16 2018-12-26 DSM IP Assets B.V. Cellules à conversion de pentose améliorée
EP2917334A1 (fr) 2012-11-07 2015-09-16 DSM IP Assets B.V. Propagation de levure à ph contrôlé
WO2014072394A1 (fr) 2012-11-09 2014-05-15 Dsm Ip Assets B.V. Procédé d'hydrolyse enzymatique de matière lignocellulosique et de fermentation de sucres
IN2015DN03027A (fr) 2012-11-09 2015-10-02 Dsm Ip Assets Bv
UA116454C2 (uk) 2012-11-09 2018-03-26 Дсм Айпі Асетс Б.В. Спосіб ферментативного гідролізу лігноцелюлозного матеріалу й ферментації цукрів
WO2014126471A1 (fr) 2013-02-15 2014-08-21 Stichting Energieonderzoek Centrum Nederland Procédé pour le traitement de biomasse lignocellulosique
NL2011164C2 (en) 2013-07-15 2015-01-21 Stichting Energie Improved process for the organosolv treatment of lignocellulosic biomass.
WO2015004098A1 (fr) 2013-07-11 2015-01-15 Dsm Ip Assets B.V. Procédé pour l'hydrolyse enzymatique de matière lignocellulosique et la fermentation des sucres
WO2015004099A1 (fr) 2013-07-11 2015-01-15 Dsm Ip Assets B.V. Procédé pour l'hydrolyse enzymatique de matière lignocellulosique et la fermentation des sucres
AR097480A1 (es) 2013-08-29 2016-03-16 Dsm Ip Assets Bv Células de levadura convertidoras de glicerol y ácido acético con una conversión de ácido acético mejorada
CN106232826A (zh) 2014-04-17 2016-12-14 国际壳牌研究有限公司 生产发酵产品的方法
US20180030482A1 (en) 2014-04-18 2018-02-01 Moralco B.V. Use of acetaldehyde in the fermentative production of ethanol
US10202622B2 (en) 2014-07-22 2019-02-12 Iogen Corporation Process for producing fuel using two fermentations
US10619173B2 (en) 2014-07-22 2020-04-14 Iogen Corporation Process for using biogenic carbon dioxide derived from non-fossil organic material
WO2016012429A1 (fr) 2014-07-24 2016-01-28 Dsm Ip Assets B.V. Cellule de levure présentant un transport amélioré du pentose
US11434509B2 (en) 2014-12-08 2022-09-06 Iogen Corporation Process for using biogenic carbon dioxide derived from non-fossil organic material
WO2016120298A1 (fr) 2015-01-28 2016-08-04 Dsm Ip Assets B.V. Procédé d'hydrolyse enzymatique d'une matière lignocellulosique et de fermentation de sucres
MY196163A (en) 2015-01-28 2023-03-17 Dsm Ip Assets Bv Process for Enzymatic Hydrolysis of Lignocellulosic Material And Fermentation of Sugars
PL3250698T3 (pl) 2015-01-28 2020-06-29 Dsm Ip Assets B.V. Sposób enzymatycznej hydrolizy materiału lignocelulozowego i fermentacji cukrów
NL1041192B1 (en) 2015-02-16 2017-01-05 Stichting Energieonderzoek Centrum Nederland Separation of lignin from organosolv liquors.
US10513714B2 (en) 2015-03-16 2019-12-24 Iogen Corporation Lignocellulosic conversion process comprising sulfur dioxide and/or sulfurous acid pretreatment
BR112017017895A2 (pt) 2015-03-16 2018-04-10 Iogen Corp processo para produzir um produto de fermentação e para produzir um álcool a partir de uma matéria prima lignocelulósica.
WO2016145530A1 (fr) 2015-03-16 2016-09-22 Iogen Corporation Procédé comprenant un prétraitement avec du dioxyde de soufre et/ou de l'acide sulfureux et hydrolyse enzymatique
WO2016169893A1 (fr) 2015-04-20 2016-10-27 Dsm Ip Assets B.V. Bouillon de fermentation complet
WO2016169892A1 (fr) 2015-04-20 2016-10-27 Dsm Ip Assets B.V. Procédé d'hydrolyse enzymatique d'une matière lignocellulosique et fermentation de sucres
FR3035405B1 (fr) 2015-04-27 2019-04-19 Lesaffre Et Compagnie Souche de levure presentant une capacite amelioree a fermenter le xylose en presence d'acide acetique
WO2016188813A1 (fr) 2015-05-22 2016-12-01 Dsm Ip Assets B.V. Cellule de levure consommant de l'acétate
WO2016207144A1 (fr) 2015-06-22 2016-12-29 Dsm Ip Assets B.V. Procédé d'hydrolyse enzymatique de matière lignocellulosique, et de fermentation de sucres
AU2016301365A1 (en) 2015-08-05 2018-03-08 Cargill, Incorporated Xylose isomerase-modified yeast strains and methods for bioproduct production
US10513715B2 (en) 2015-09-24 2019-12-24 Iogen Corporation Wet oxidation of biomass
CN108603179B (zh) 2015-10-06 2022-02-08 帝斯曼知识产权资产管理有限公司 发酵产物生产增加的真核细胞
US10889795B2 (en) 2015-11-25 2021-01-12 Iogen Energy Corporation System and method for cooling pretreated biomass
CA3006672A1 (fr) 2015-12-18 2017-06-22 Iogen Corporation Pretraitement au dioxyde de soufre et/ou a l'acide sulfureux
WO2017136915A1 (fr) 2016-02-10 2017-08-17 Iogen Corporation Prétraitement de biomasse lignocellulosique avec du dioxyde de soufre et/ou de l'acide sulfureux
US11667680B2 (en) 2016-03-18 2023-06-06 Lallemand Hungary Liquidity Management Llc Regulation of the RAS/cAMP/PKA signaling pathway in yeasts for obtaining a fermentation product during fermentation
EP3469090A1 (fr) 2016-06-09 2019-04-17 DSM IP Assets B.V. Train de graines pour la production d'enzymes à grande échelle
US10913938B2 (en) 2016-07-29 2021-02-09 Dsm Ip Assets B.V. Polypeptides having cellulolytic enhancing activity and uses thereof
WO2018073107A1 (fr) 2016-10-19 2018-04-26 Dsm Ip Assets B.V. Cellule eucaryote comprenant de la xylose isomérase
US20190271017A1 (en) 2016-11-04 2019-09-05 Inbicon A/S Method for preparing fermentable sugars from lignocellulosic biomass
CN109996883A (zh) 2016-11-24 2019-07-09 帝斯曼知识产权资产管理有限公司 酶组合物
US11499142B2 (en) 2016-11-24 2022-11-15 Dsm Ip Assets B.V. Enzyme composition
CN110088275A (zh) 2016-12-23 2019-08-02 帝斯曼知识产权资产管理有限公司 改进的无甘油的乙醇生产
FR3062134B1 (fr) 2017-01-24 2023-07-21 Lesaffre & Cie Obtention de souches de levure performantes pour la metabolisation de l'arabinose
WO2018172328A1 (fr) 2017-03-21 2018-09-27 Dsm Ip Assets B.V. Production améliorée d'éthanol sans glycérol
WO2018185071A1 (fr) 2017-04-03 2018-10-11 Dsm Ip Assets B.V. Procédé pour l'hydrolyse enzymatique de matière lignocellulosique et la fermentation de sucres
WO2018228836A1 (fr) 2017-06-13 2018-12-20 Dsm Ip Assets B.V. Cellule de levure recombinée
CA3073329A1 (fr) 2017-09-26 2019-04-04 Dsm Ip Assets B.V. Procede ameliore pour la production d'ethanol
CN111133111A (zh) 2017-09-26 2020-05-08 帝斯曼知识产权资产管理有限公司 消耗乙酸的菌株
US11274310B2 (en) 2017-09-29 2022-03-15 Dsm Ip Assets B.V. Yeast cells for glycerol free ethanol production
US11384368B2 (en) 2017-09-29 2022-07-12 Dsm Ip Assets B.V. Glycerol free ethanol production
LT3695001T (lt) 2017-10-09 2024-02-26 Versalis S.P.A. Lignoceliuliozinės medžiagos fermentinės hidrolizės ir cukrų fermentacijos būdas
WO2019086369A1 (fr) 2017-10-30 2019-05-09 Dsm Ip Assets B.V. Procédé pour l'hydrolyse enzymatique de matière lignocellulosique et la fermentation de sucres
WO2019086370A1 (fr) 2017-10-30 2019-05-09 Dsm Ip Assets B.V. Procédé pour l'hydrolyse enzymatique de matière lignocellulosique et la fermentation de sucres
US11299850B2 (en) 2017-11-09 2022-04-12 Iogen Corporation Converting lignocellulosic biomass to glucose using a low temperature sulfur dioxide pretreatment
CA3078833A1 (fr) 2017-11-09 2019-05-16 Iogen Corporation Pretraitement a basse temperature a l'aide de dioxyde de soufre
US11326172B2 (en) 2017-11-14 2022-05-10 Dsm Ip Assets B.V. Polypeptides with improved arabinose transport specificity
WO2019110492A1 (fr) 2017-12-08 2019-06-13 Dsm Ip Assets B.V. Cellule de levure recombinante
WO2019110491A1 (fr) 2017-12-08 2019-06-13 Dsm Ip Assets B.V. Cellule de levure recombinée
EP3746546A1 (fr) 2018-02-01 2020-12-09 DSM IP Assets B.V. Cellule de levure capable de fermenter simultanément des sucres hexose et pentose
WO2019185681A1 (fr) 2018-03-28 2019-10-03 Dsm Ip Assets B.V. Composition enzymatique
BR112020018791A2 (pt) 2018-03-28 2020-10-13 Dsm Ip Assets B.V. composição de enzima
EP3775243A4 (fr) 2018-04-06 2022-02-09 Iogen Corporation Prétraitement avec de l'acide lignosulfonique
WO2019219804A1 (fr) 2018-05-17 2019-11-21 Dsm Ip Assets B.V. Procédé de production d'un polypeptide
RS64143B1 (sr) 2018-05-30 2023-05-31 Versalis Spa Postupak za proizvodnju šećera iz ugljenohidratnih materijala
WO2020043497A1 (fr) 2018-08-28 2020-03-05 Dsm Ip Assets B.V. Processus de production d'éthanol
WO2020058249A1 (fr) 2018-09-18 2020-03-26 Dsm Ip Assets B.V. Procédé pour l'hydrolyse enzymatique de matière glucidique et la fermentation de sucres
WO2020058253A1 (fr) 2018-09-18 2020-03-26 Dsm Ip Assets B.V. Procédé d'hydrolyse enzymatique de matière glucidique et fermentation de sucres
WO2020058248A1 (fr) 2018-09-18 2020-03-26 Dsm Ip Assets B.V. Procédé d'hydrolyse enzymatique de matière glucidique et fermentation de sucres
JP7078900B2 (ja) 2018-10-05 2022-06-01 トヨタ自動車株式会社 形質転換酵母及びこれを用いたエタノールの製造方法
CN113544280A (zh) 2019-03-12 2021-10-22 帝斯曼知识产权资产管理有限公司 用于产生发酵液的方法
US20220340943A1 (en) 2019-09-10 2022-10-27 Dsm Ip Assets B.V. Enzyme composition
CN114667347A (zh) 2019-11-08 2022-06-24 帝斯曼知识产权资产管理有限公司 用于生产乙醇的方法
US20230002794A1 (en) 2019-12-10 2023-01-05 Novozymes A/S Microorganism for improved pentose fermentation
CN117157410A (zh) 2021-04-06 2023-12-01 帝斯曼知识产权资产管理有限公司 酶组合物
BR112023020448A2 (pt) 2021-04-06 2023-11-21 Dsm Ip Assets Bv Composição enzimática
BR112023020370A2 (pt) 2021-04-06 2023-11-21 Dsm Ip Assets Bv Composição de enzimas
CA3197143A1 (fr) 2021-04-08 2022-10-13 Versalis S.P.A. Procede de preparation d'un produit a base de sucre et d'un produit de fermentation
BR112023025624A2 (pt) 2021-06-07 2024-02-27 Novozymes As Célula de levedura recombinante, célula hospedeira recombinante, composição, cocultura, métodos de produção de um derivado de uma célula hospedeira recombinante e de produção de um produto de fermentação, e, uso de uma célula hospedeira recombinante
WO2023079050A1 (fr) 2021-11-04 2023-05-11 Dsm Ip Assets B.V. Cellule de levure recombinée
WO2023079049A1 (fr) 2021-11-04 2023-05-11 Dsm Ip Assets B.V. Polypeptide variant et cellule de levure recombinée
WO2023079048A1 (fr) 2021-11-04 2023-05-11 Dsm Ip Assets B.V. Procédé de production d'éthanol et cellule de levure recombinante

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080261287A1 (en) * 2004-07-16 2008-10-23 Aaron Adriaan Winkler Metabolic Engineering of Xylos Fermentation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0202090D0 (sv) 2002-05-08 2002-07-04 Forskarpatent I Syd Ab A modifierd yeast consuming L-arabinose
EP1863901A1 (fr) * 2005-03-11 2007-12-12 Forskarpatent i Syd AB Souches de saccharomyces cerevisiae capables de faire fermenter l'arabinose et le xylose

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080261287A1 (en) * 2004-07-16 2008-10-23 Aaron Adriaan Winkler Metabolic Engineering of Xylos Fermentation

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110104736A1 (en) * 2008-03-13 2011-05-05 Jacobus Thomas Pronk Selection of organisms capable of fermenting mixed substrates
US10260075B2 (en) 2009-07-10 2019-04-16 Dsm Ip Assets B.V. Fermentative production of ethanol from glucose, galactose and arabinose employing a recombinant yeast strain
US11649471B2 (en) 2009-07-10 2023-05-16 Dsm Ip Assets B.V. Fermentative production of ethanol from glucose, galactose and arabinose employing a recombinant yeast strain
US9551015B2 (en) 2009-07-10 2017-01-24 Dsm Ip Assets B.V. Fermentative production of ethanol from glucose, galactose and arabinose employing a recombinant yeast strain
US10982235B2 (en) 2009-07-10 2021-04-20 Dsm Ip Assets B.V. Fermentative production of ethanol from glucose, galactose and arabinose employing a recombinant yeast strain
US11421256B2 (en) 2009-10-08 2022-08-23 Dsm Ip Assets B.V. Process for enzymatic hydrolysis of lignocellulosic material and fermentation of sugars
EP2561064B1 (fr) 2010-04-21 2017-10-18 DSM IP Assets B.V. Cellule adaptée à la fermentation d' une composition de sucres mixtes
WO2012009272A2 (fr) * 2010-07-14 2012-01-19 Codexis, Inc. Fermentation de pentose par un micro-organisme recombinant
WO2012009272A3 (fr) * 2010-07-14 2012-03-01 Codexis, Inc. Fermentation de pentose par un micro-organisme recombinant
US20140141473A1 (en) * 2011-04-22 2014-05-22 Dsm Ip Assets B.V. Yeast cell capable of converting sugars including arabinose and xlose
US20130035515A1 (en) * 2011-06-17 2013-02-07 Butamax(Tm) Advanced Biofuels Llc Lignocellulosic hydrolysates as feedstocks for isobutanol fermentation
US9598689B2 (en) 2011-11-10 2017-03-21 Lallemand Hungary Liquidity Management Llc Genetically modified strain of S. cerevisiae engineered to ferment xylose and arabinose
US10047380B2 (en) 2011-11-10 2018-08-14 Lallemand Hungary Liquidity Management Llc Genetically modified strain of S. cerevisiae engineered to ferment xylose and arabinose
CN104039806A (zh) * 2011-11-10 2014-09-10 马斯科马公司 被加工为发酵木糖和阿拉伯糖的啤酒酵母的遗传修饰菌株
WO2013071112A1 (fr) * 2011-11-10 2013-05-16 Mascoma Corporation Souche génétiquement modifiée de s. cerevisiae conçue pour fermenter le xylose et l'arabinose
US10689670B2 (en) 2016-06-14 2020-06-23 Dsm Ip Assets B.V. Recombinant yeast cell
US11186850B2 (en) 2016-06-14 2021-11-30 Dsm Ip Assets B.V. Recombinant yeast cell

Also Published As

Publication number Publication date
AU2007302867B2 (en) 2013-11-07
CA2664646C (fr) 2016-09-20
US9303253B2 (en) 2016-04-05
WO2008041840A1 (fr) 2008-04-10
AU2007302867A1 (en) 2008-04-10
EA200900512A1 (ru) 2009-08-28
US20120208231A1 (en) 2012-08-16
EP2069476B1 (fr) 2016-08-10
JP2014094011A (ja) 2014-05-22
JP2010505411A (ja) 2010-02-25
EA016303B1 (ru) 2012-04-30
JP5553433B2 (ja) 2014-07-16
MX2009003501A (es) 2009-04-16
CA2664646A1 (fr) 2008-04-10
EP2069476A1 (fr) 2009-06-17
JP5846456B2 (ja) 2016-01-20

Similar Documents

Publication Publication Date Title
US9303253B2 (en) Metabolic engineering of arabinose-fermenting yeast cells
JP5796925B2 (ja) キシロース発酵性真核細胞の代謝工学
US8399215B2 (en) Pentose sugar fermenting cell
US20150184203A1 (en) Novel arabinose-fermenting eukaryotic cells
EP1468093B1 (fr) Fermentation de sucres pentose
US20110104736A1 (en) Selection of organisms capable of fermenting mixed substrates
US10100320B2 (en) Pentose sugar fermenting cell
US20110189728A1 (en) Pentose sugar fermenting cell
WO2009109630A1 (fr) Cellule de fermentation de sucre pentose
DK2069476T3 (en) Metabolic MODIFICATION of arabinose-fermenting YEAST CELLS
Winkler et al. Metabolic engineering of xylose fermenting eukaryotic cells
BR112014002709A2 (pt) célula de fermentação de açúcar pentose

Legal Events

Date Code Title Description
AS Assignment

Owner name: DSM IP ASSETS B.V.,NETHERLANDS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VAN MARIS, ANTONIUS J.A.;PRONK, JACOBUS THOMAS;WISSELINK, HENDRIK W.;AND OTHERS;SIGNING DATES FROM 20090423 TO 20090528;REEL/FRAME:022837/0186

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION